TICKERNERD
Menu
CRBPCRBPHealthcare · Biotechnology

CRBP Stock Forecast: Corbus Pharmaceuticals Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$10
+0.10% on the day

The 10 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. hold a median 12-month price target of $35 — +246.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$195.2M
Ticker Nerd rank
26 / 100
Median analyst target
$35
Analysts covering
10
Total return, dividends reinvested
1W
−0.8%
1M
+11.7%
YTD
+24.0%
1Y
+4.8%
From 52W high
−47.9%
From 52W low
+36.7%
$7
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRBP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corbus Pharmaceuticals Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
76
Size
69
Momentum
51
Quality
47
Value
38
Volatility
37
Revisions
28
Growth
17
Issuance
14

Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRBP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRBP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26CRBPHigh $48Median $35Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $17Median $35High $48

The green dot is the last close — the median target sits +246.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
7 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $35
7 Aug 2026OppenheimerMaintainsOutperform$52 → $48
23 June 2026MizuhoMaintainsOutperform$44 → $34
23 June 2026MizuhoMaintainsOutperform—
17 June 2026OppenheimerMaintainsOutperform$54 → $52
17 June 2026OppenheimerMaintainsOutperform—
27 May 2026WedbushMaintainsOutperform—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026MizuhoMaintainsOutperform—
13 May 2026GuggenheimReiteratesBuy—
13 May 2026JefferiesMaintainsBuy—
13 May 2026OppenheimerMaintainsOutperform—
29 Apr 2026GuggenheimInitiatesBuy—
10 Mar 2026OppenheimerMaintainsOutperform—
13 Nov 2025RBC CapitalMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025WedbushMaintainsOutperform—
17 Sept 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025OppenheimerMaintainsOutperform—
7 May 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRBP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRBP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
4
Fundamentals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−95.6%

Higher than 13% of US stocks

Return on assets
−53.0%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRBP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRBPCorbus Pharmaceuticals Holdings, Inc.$195.2M
26
ORMPOramed Pharmaceuticals, Inc.$183.7M
75
KRROKorro Bio, Inc.$191.5M
29
ABOSAcumen Pharmaceuticals, Inc.$192.8M
42
CHRSCoherus Oncology, Inc.$179.4M
53
VYGRVoyager Therapeutics, Inc.$194.9M
74
PLXProtalix Biotherapeutics, Inc.$178.9M
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corbus Pharmaceuticals Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRBP news & analysis

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

GlobeNewsWire · 4 Aug 2026positive

Corbus Pharmaceuticals announced the last patient has completed their final visit in the CANYON-1 Phase 1b trial of CRB-913 for obesity, with topline data expected in September 2026. The study follows a Phase 1a trial that showed differentiated gastrointestinal tolerability compared to GLP-1 class drugs.

Why it matters — The completion of patient visits brings Corbus a step closer to topline data for CRB-913, which showed promising tolerability and significantly lower brain penetration than monlunabant in earlier studies.

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

GlobeNewsWire · 28 July 2026positive

Corbus Pharmaceuticals announced FDA clearance to initiate the TEMPO-1 registrational study of CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma (OPSCC), with enrollment expected to begin in September 2026.

Why it matters — This FDA clearance allows Corbus to advance CRB-701, a next-generation Nectin-4 ADC, into a registrational study for a common head and neck cancer with approximately 14,000 eligible US patients annually.

FAQ

Frequently asked questions about CRBP stock

What is the CRBP stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. have a median 12-month price target of $35, with estimates ranging from $17 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRBP stock a buy right now?

Of the 10 analysts covering Corbus Pharmaceuticals Holdings, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corbus Pharmaceuticals Holdings, Inc. 26 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRBP?

As at 15 Aug 2026, Corbus Pharmaceuticals Holdings, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).

Will CRBP stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +246.9% from the last close, and Ticker Nerd's factor model ranks Corbus Pharmaceuticals Holdings, Inc. 26 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRBP stock forecast for 2030?

No analyst covering Corbus Pharmaceuticals Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $48 over the next 12 months.

How has CRBP stock performed over the past year?

Corbus Pharmaceuticals Holdings, Inc. returned +4.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corbus Pharmaceuticals Holdings, Inc. do?

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for oncology and obesity.

What is the latest news on CRBP?

The most recent item we track (GlobeNewsWire, 4 Aug 2026): "Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity". Corbus Pharmaceuticals announced the last patient has completed their final visit in the CANYON-1 Phase 1b trial of CRB-913 for obesity, with topline data expected in September 2026. The study follows a Phase 1a trial that showed differentiated gastrointestinal tolerability compared to GLP-1 class drugs.

Company

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for oncology and obesity. The company advances a pipeline of targeted treatments, including CRB-701, a next-generation antibody drug conjugate that targets Nectin-4 expression on cancer cells to deliver a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody designed to block TGFβ activation on cancer cells; and CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist aimed at obesity treatment. These candidates focus on well-understood biological pathways to address serious unmet medical needs in cancer care and weight management. Corbus Pharmaceuticals Holdings, Inc. conducts rigorous clinical trials to evaluate safety, tolerability, and efficacy, with programs in advanced stages for solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and bladder cancer, as well as obesity studies showing promising early weight loss data. Headquartered in Norwood, Massachusetts, the company operates in the high-stakes biopharma sector, emphasizing precision medicine to improve patient outcomes in critical therapeutic areas.

CEO Dr. Yuval Cohen Ph.D. · 36 employees · United States · https://www.corbuspharma.com